Biopharmaceutical Contract Research, Development & Manufacturing (CRDMO/CDMO)
Strategic Profile
WuXi Biologics reported 2024 revenue growth of 9.6% YoY to RMB 18,675.4 million, driven by non-COVID revenue up 13.1%. The company maintains a total backlog of US$18.5 billion and has strengthened its global presence with facility expansions in Ireland, Singapore, and the U.S. The company's positioning as a leading global CRDMO with proprietary antibody platforms positions it favorably within the high-growth biologics outsourcing market.
Cyborg Score Rationale
WuXi reported solid 2024 results with 9.6% revenue growth and 14.4% adjusted EBITDA growth to RMB7,999.3 million. The company was awarded CDMO of the Year at the Asia Pacific Biologics CDMO Excellence Awards 2025. However, geopolitical headwinds related to U.S.-China relations present ongoing risk.
Top Insights
Non-COVID revenue surged 13.1% in 2024, indicating strong core business momentum beyond pandemic-driven contracts
WuXi plans to expand total biopharmaceutical production capacity beyond 430,000 liters across major regions
Company completed first commercial PPQ at its Hangzhou site's 15,000L single-use bioreactor line, Asia's first 3 x 5,000L setup, in April 2025
U.S. Congress has expressed national security concerns regarding the company's alleged ties to the People's Liberation Army, creating regulatory risk
Named Competitors
Lonza — Global CRDMO with comprehensive biologics and small molecule capabilities
Samsung BioLogics — Integrated biopharmaceutical manufacturing and development services
Fujifilm Diosynth — Contract development and manufacturing services for biologics
Catalent — Global CDMO serving biologics and pharmaceuticals sectors
Recent Developments
(February 2026) Awarded EcoVadis Platinum Medal for third consecutive year, ranking among top 1% globally for sustainability
(January 2025) Signed agreement with MSD International for asset transfer of Dundalk, Ireland vaccine facility
(April 2025) Completed first commercial PPQ campaign at Hangzhou site's 15,000L production line with proprietary process innovations
Open the full interactive WuXi Biologics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.